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Background: Thalassemia is a common disorder worldwide with a predominant incidence in Mediterranean countries,
North Africa, the Middle East, India, Central Asia, and Southeast Asia. Whilst substantial progress has been made
towards the improvement of Health related quality of life (HRQoL) in western countries, scarce evidence-based data
exists on HRQol of thalassemia children and adolescents living in developing countries.
Methods: We studied 60 thalassemia children from Middle Eastern countries with a median age of 10 years (range 5 to
17 years). HRQoL was assessed with the Pediatric Quality of Life Inventory (PedsQL) 4.0. The Questionnaire was
completed at baseline by all patients and their parents. The agreement between child-self and parent-proxy HRQoL
reports and the relationship between HRQoL profiles and socio-demographic and clinical factors were investigated.
Results: The scores of parents were generally lower than those of their children for Emotional Functioning (mean 75 vs
85; p = 0.002), Psychosocial Health Summary (mean 70.3 vs 79.1; p = 0.015) and the Total Summary Score (mean 74.3 vs
77.7 p = 0.047). HRQoL was not associated with ferritin levels, hepatomegaly or frequency of transfusions or iron
chelation therapy. Multivariate analysis showed that a delayed start of iron chelation had a negative impact on total
PedsQL scores of both children (p= 0.046) and their parents (p= 0.007).
Conclusions: The PedsQL 4.0 is a useful tool for the measurement of HRQoL in pediatric thalassemia patients. This
study shows that delayed start of iron chelation has a negative impact on children’s HRQoL.
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Thalassemia is an autosomal recessive congenital disease
originating from countries of the Mediterranean region.
Deficiencies in globin chain synthesis may lead to severe
anemia requiring regular blood transfusions and iron che-
lation therapy starting at an early age. Despite the
advances made in treatment over the past decades, many
patients with beta-thalassemia major, especially those liv-
ing in developing countries, do not have access to conven-
tional and/or innovative treatment approaches. The
introduction of new drugs capable of reducing the accu-
mulation of iron in body organs, particularly the heart,* Correspondence: gcaocci@alice.it
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reproduction in any medium, provided the orliver and pancreas, has dramatically improved survival
rates [1,2]. But although the number of living patients
continues to rise, numerous challenges remain, such as
endocrine problems, a high frequency of chronic hepatitis
C as well as psychosocial morbidity associated with
chronic disease [3]. Poor compliance with iron chelation
therapy is another prominent unsolved problem which,
today, mostly arises from the unavailability of oral iron-
chelators.
Beta thalassemia major is a serious life-limiting and
potentially life-threatening condition that causes substantial
disruption in education and social activities. Children often
need to miss school because of hospital appointments or
admissions for regular monthly blood transfusion and/or
treatment of complications. Their self identity is compro-
mised and they become increasingly dependent upon
others [4]. Patients and their families are conscious of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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constant reminder that they are “different”, making it
practically impossible to lead a normal life. Overall, the psy-
chosocial burden affects many aspects of the patient’s life
such as education, free-time, physical activities, skills, cap-
abilities and family adjustment, the effects of which often
result in anxiety, isolation and depression.
Health Related Quality of Life (HRQoL) is generally
conceptualized as a multidimensional construct referring
to patients’ perceptions of the impact of disease and
treatment on their physical, psychological and social
functioning and well-being [5,6] Several studies have
investigated HRQoL in thalassemia patients but the dif-
ferent types of questionnaires used in the past makes it
difficult to perform direct comparisons of the outcomes
[7-10]. A major breakthrough came in 2003 when Varni
and colleagues created the multidimentional PedsQL 4.0
questionnaire to measure the essential core domains for
pediatric HRQoL: Physical Functioning, Emotional
Functioning and Social Functioning, as delineated by the
World Health Organization (WHO), as well as School
Functioning [11,12]. The child self and parent proxy-
reports of the PedsQL 4.0 measurement model are sensi-
tive to cognitive development and contain appropriate
forms for children and their parents. Some recent papers
have used PedsQL 4.0 to assess HRQoL in thalassemia
patients from developing countries [13-18].
However, given the paucity of research in this area and
the need to rely on additional evidence-based data to
further improve patient care, we conducted a study to
investigate the sociodemographic and clinical factors
associated with HRQoL of thalassemia children living in
Middle Eastern countries. Considering that previous
studies of childhood illness have shown that parents’
ratings of their child’s HRQoL tend to be lower and pos-
sibly reflect parental distress [19,20], we also evaluated
the differences between HRQoL reports of the children
and their parent-proxies.
Methods
Patients and features
From November 2007 to August 2008, we performed a
cross-sectional study on a group of 60 thalassemia chil-
dren and their parents, all originally coming from coun-
tries of the Middle East (i.e. Kurdistan, Palestine, Libya,
Iraq and Syria). Thirty patients came to Italy to receive
hematopoietic stem cell transplantation as part of a larger
humanitarian project involving a knowledge exchange
program with the local doctors. Only patients under the
age of 18 years with a genetically confirmed diagnosis of
beta-thalassemia were included in the study. The data col-
lected both in Italy and the Middle-East were sent to the
Italian Hematology Centers in Milan (San Raffaele Hos-
pital) and Cagliari (R. Binaghi Hospital) for statisticalanalysis and evaluation. Questionnaires were administered
in the Thalassemia Center of the Hevi Pediatric Hospital
(Duhok, Iraq) immediately before transfusing patients and
at the Binaghi Hospital (Italy) and San Raffaele Hospital
(Italy) one month before bone marrow transplantation.
Written informed consent was provided by the patients’
parents according to the declaration of Helsinki. The par-
ticipants were fully informed and aware of the research
objectives. The study was approved by the local ethics
committee in Cagliari (Authorization n° 58/2006).
Health related quality of life evaluation
HRQoL was assessed using the PedsQL 4.0 Generic Core
Scales. This 23-item multidimentional model encompasses
the essential core domains for pediatric HRQoL measure-
ment: Physical Functioning (8 items), Emotional Function-
ing (5 items) and Social Functioning (5 items), as
delineated by the World Health Organization (WHO), as
well as School Functioning (5 items) [11,12]. Additionally,
the PedsQL 4.0 questionnaire contains a Psychosocial
Health Summary Score which represents the sum of items
over the number of items answered in the Emotional,
Social and School functioning scales [21]. To create the
total PedsQL score, the mean is computed as the sum of
all items over the number of items answered on all scales.
The child self and parent proxy-reports of the PedsQL
measurement model are sensitive to cognitive develop-
ment and contain appropriate forms for children aged 5–
7, 8–12 and 13–18 years and their parents. The reliability,
internal consistency and validity of the PedsQL question-
naire have been assessed in pediatric populations with
acute and chronic health conditions, besides in physically
healthy pediatric populations [11,12]. Each item is rated
on a 5-point Likert scale from 0 (Never) to 4 (Almost al-
ways) and on a 3-point scale for young children (5–
7 years): 0 (Not at all), 2 (Sometimes) and 4 (A lot). The
scores for each dimension are calculated as follows: the
mean score is represented by the sum of the items over
the number of items answered; missing values are replaced
by the mean score of the remaining items; if more than
50% of the items in a given scale are missing, the scale
scores are not computed. Raw scores are transformed into
standardized scores on a scale from 0 to 100 with higher
scores representing higher functioning levels.
For logistic reasons, the PedsQL 4.0 Generic Core
Scales were administered both in homeland countries
(50%) and in Italy (50%). The arabic version of this ques-
tionnaire was validated by Garaibhe et al. in 2011 on a
cohort of 128 Jordan thalassemia patients [18] (Table 1).
Our cohort of patients and parents all spoke the Arabic
language. Questionnaires in the Arabic language were
completed independently by children above 8 years and
their parents. Children aged 5–7 years were questioned
by trained interviewers.
Table 1 Overview of studies evaluating HRQoL with PEDsQL in pediatric patients with thalassemia. NR=not reported
Study Sample and
nationality
Physical
functioning
mean (SD)
Emotional
functioning
mean (SD)
Social
functioning
mean (SD)
School
functioning
mean (SD)
Psychosocial
summary score
mean (SD)
Total
summary score
mean (SD)
Patients Parents Patients Parents Patients Parents Patients Parents Patients Parents Patients Parents
Ismail et al. 2006
[13]
78 Malaysia 69.1
(16.4)
NR 68.1
(17.2)
NR 74.3
(18.7)
NR 60.1
(16.4)
NR 67.58
(12.8)
NR 68.9
(12.1)
NR
Cheuk et al. 2008
[14]
25 Hong
Kong
66.7
(16.0)
NR 60.8
(17.1)
NR 82.5
(17.7)
NR 75.4
(19.5)
NR 72.9
(13.6)
NR NR NR
Clarke et al.
2009 [15]
22 UK NR 66.5
(21.8)
NR 73.6
(22.7)
NR 77.6
(19.9)
NR 60.9
(27.5)
NR 68.3
(19.7)
NR 69.1
(18.1)
Thavorncharoensap
et al. 2010 [16]
315 Thailand 78.2
(14.8)
NR 75.9
(16.6)
NR 83.7
(14.7)
NR 67.9
(15.9)
NR 75.5
(12.8)
NR 76.7
(11.4)
NR
Surapolchai et al. 2010
[17]
54 Thailand 79.6
(2.3)
72.2
(2.6)
NR NR NR NR NR NR 77.4
(2.3)
74.6
(2.2)
78.5
(2.1)
73.4
(2.2)
Garaibeh et al. 2011
[18]
128 Jordan 54.2
(15.1)
NR 62.4
(23.3)
NR 73.3
(20.9)
NR 46.7
(21.1)
NR NR NR 59.2
(16.3)
NR
This report 2012 60 Middle
East
68,4
(27,2)
67,1
(28,0)
76,9
(24,6)
71,7
(25,3)
76,4
(20,6)
73,9
(23,2)
69,4
(21,4)
67,9
(21,4)
73,6
(20,0)
69,6
(20,2)
71,9
(20,6)
69,3
(19,9)
Caocci et al. BMC Blood Disorders 2012, 12:6 Page 3 of 7
http://www.biomedcentral.com/1471-2326/12/6Statistical analysis
The clinical and demographic features of the patients were
presented in terms of percentages, median, mean, standard
deviation and range. Descriptive measures for PedsQL
domains were reported as median and inter-quartile ranges.
Because of the non-normality of responses, differences be-
tween patient and parent responses on the PedsQL 4.0
were analyzed using the paired Wilcoxon signed rank test.
The differences were expressed as (pseudo) median with
95% confidence intervals. Different responses of boys and
girls to items within a domain, as well as ferritin levels
above 1300 mg/dl (Yes/No), Hepatomegaly (Yes/No),
transfusion and iron chelation frequency (regular/slightly ir-
regular/irregular), were analyzed using the Mann–Whitney
test. Cut-off points were based on standard clinical guide-
lines. Ferritin values above 1300 μg/dl clearly suggest liver
iron overload (Table 2).
Association between patient characteristics and the
total PedsQL score was analyzed by univariate linear re-
gression. Multivariable linear regression models using
the PedsQL score as the outcome (which was normally
distributed) and the patient characteristics as predictors
were constructed using Bayesian model averaging [22].
Results
The 60 children and parents invited to participate in the
study completed the PedsQL questionnaire with a response
rate of 100%. Patient clinical and socio-demographic char-
acteristics are shown in Table 2. Despite the fact that beta-
thalassemia major was diagnosed at a median age of
8 months and that blood transfusions were started at a me-
dian age of 11.5 months, there was a significant delay in the
start of iron chelation therapy, reaching a median of
49 months (range 12–120) after birth. Only 22% of the
children had been offered regular transfusion support (pre-transfusion hemoglobin value≥9gr/dl) and 78% of the
patients had either received irregular iron chelation therapy
(less than once a week) or none at all. Seventy-seven per-
cent of the patients had hepatomegaly which in most cases
(65%) was due to coexisting chronic hepatitis B or C; 78%
of the patients had ferritin values above 1300 μg/dl
(Table 2).
HRQoL based on clinical and sociodemographic
characteristics
No statistically significant differences were found for any
of the PedsQL domains after categorizing patients
according to ferritin levels, hepatomegaly, frequency of
transfusions and iron chelation therapy. A borderline
difference (p = 0.047) was found for gender within the
PedsQL School domain. Girls had higher median scores
than boys: 80 (range, 65.4 to 90) and 70 (range, 45 to
80), respectively.
Further analysis was performed to investigate the global
child and parent ratings for well-being (total PedsQL score)
and the association with clinical and demographic features.
Univariate and multivariate analysis showed that a delayed
start of iron chelation had a negative impact on total
PedsQL scores both in children (p=0.046) and parent
reports (p=0.007). No significant association was found
with any of the other factors considered (sex, age at diagno-
sis, age at first transfusion, transfusion frequency, hepato-
megaly, hepatitis, ferritin above 1300 mg/dl, frequency of
iron chelation) (Table 3). No differences were observed
between patients who received supportive care in the Mid-
dle East and those treated in Italy before transplantation.
Child self and parent proxy-reports of HRQoL
Table 4 reports the differences in child and parent PedsQL
domain scores, expressed as medians and inter-quartile
Table 2 Clinical and socio-demographic characteristics of
60 thalassemia children
Characteristic n (%)
Age; median (range) 10.0 (5 to 17) years
Sex
Male 34 (57)
Female 26 (43)
Country of origin
Kurdistan 10 (17)
Libya 8 (13)
Palestine 1 (2)
Syria 10 (17)
Iraq 31 (52)
Age at diagnosis in months;
median (range)
8 (1 to 48)
Age at first transfusion in months;
median (range)
11.5 (2 to 60)
Age at start of iron chelation in months;
median (range)
49 (12 to 120)
Transfusion frequency
Regular (pre-transfusion hemoglobin≥ 9gr/dl) 13 (22)
Fairly irregular (pre-transfusion
hemoglobin≥ 7.5 and<9 gr/dl)
34 (57)
Irregular (Pre-transfusion hemoglobin
<7.5 gr/dl or frequent transfusion reactions)
13 (22)
Hepatomatology> 2 cm
Yes 46 (77)
No 13 (22)
Unknown 1 (2)
Hepatitis
Yes 39 (65)
No 21 (35)
Ferritin >1300 ng/ml
Yes 47 (78)
No 13 (22)
Iron chelation
Regular administration (once-daily) 13 (22)
Slightly irregular administration
(at least once a week)
29 (48)
Irregular administration
(less than once a week or none)
16 (27)
None 2 (3)
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child self and parent proxy-ratings, it was found that
parents tended to slightly underestimate their child’s
HRQoL. The scores of parents were lower for Emotional
Functioning (median 75 vs 85; p = 0.002), Psychosocial
Health Summary (median 70.3 vs 79.1; p = 0.015) and the
Total Summary Score (median 74.3 vs 77.7 p= 0.047)
(Table 4). Multivariate analysis did not reveal any associa-
tions with age or gender in either patients or their parents.Discussion
Pediatric assessment of HRQoL has traditionally been
based on reports compiled by parents, which may not
reflect the child’s perceptions. On this ground, we inves-
tigated both the parents’ perceptions and the child’s
perceptions of disease and treatment-related burden.
The value of combining child self and parent proxy-
reports to investigate health, functioning, abilities and
emotions in children, is increasingly recognized [20].
The main evidence emerging from this cross-sectional
analysis was that a delayed start of iron chelation was in-
dependently associated with a negative impact on the
total PedsQL score (Table 3). Interestingly, this inde-
pendent association was confirmed by both child self
and parent proxy-reports. Delayed iron chelation can
lead to excessive accumulation of iron in body organs.
Health issues arise especially when excess iron is stored
in the heart, liver or pancreas.
This finding underlines the need for early and appro-
priate scheduling of routine iron chelation therapy in
these patients. The introduction of promising new oral
iron chelators has significantly improved depletion of
iron stores in patients, with a major impact on well-
being and survival [1,2]. However, in developing coun-
tries the cost of iron chelation is either too expensive or
not available and iron overload in pediatric thalassemia
patients is a common finding.
When we investigated the differences between PedsQL
median scores of children and their parents, we found that
parent scores were lower for Emotional Functioning,
Psychosocial Health Summary and the Total Summary
Score (Table 4). It would appear that parents tend to con-
sider HRQoL of their children more compromised in
domains dealing with interpersonal relationships, rather
than those concerning physical impairment. A possible
explanation may be that parents of thalassemia children
unconsciously project their pessimistic feelings onto their
child’s functioning. Creemens et al. [20] speculated that
several factors influenced the agreement between child self
and parent proxy-reports using the PedsQL generic core
scales. They retain that much depends upon the domain
being measured, with higher agreement for the physical
aspects of health compared to emotional or social aspects.
Furthermore, they postulated that in the healthy popula-
tion, agreement between child and parent proxy-reports of
child HRQoL may be affected by the child’s age and the
parents’ own HRQoL. In contrast with our findings, the
only previous study of thalassemia children to assess both
patient and the parent perspectives, showed a good level
of agreement between child and parent reports [17].
Hence, further research will be required to explore
whether parent–child agreement is dependent on add-
itional factors, such as the parent-to-child relationship
(mother vs father) or different types of disease.
Table 3 Univariate and multivariable linear regression analyses of association between clinical and demographic
characteristics and total PEDsQL scores in thalassemia patients and parents
Characteristic Total PEDSQL score (patients) Total PEDSQL score (parents)
Univariateβ (95% CI) Multivariableβ (95% CI) Univariateβ (95% CI) Multivariableβ (95% CI)
Sex 1.49 (95% CI −9.09 to 12.07)
p = 0.783
- 4.40 (95% CI −5.81 to 14.61)
p = 0.401
-
Age at diagnosis 0.22 (95% CI −0.20 to 0.63)
p = 0.311
- −0.01 (95% CI −0.42 to 0.39)
p = 0.959
-
Age at first
transfusion
0.15 (95% CI −0.22 to 0.53)
p = 0.423
- −0.12 (95% CI −0.48 to 0.25)
p = 0.528
-
Age at start of
iron chelation
−0.17 (95% CI −0.33 to 0)
p = 0.046
−0.17 (95% CI −0.33 to 0)
p = 0.046
−0.21(95% CI −0.36 to –0.06)
p = 0.007
−0.21(95% CI −0.36 to –0.06)
p = 0.007
Transfusion Frequency 7.04 (95% CI −5.56 to 19.65)
p = 0.278
- 3.30 (95% CI −9.03 to 15.63)
p = 0.602
-
Hepatomegaly 1.46 (95% CI −11.41 to 14.32)
p = 0.278
- 5.11 (95% CI −7.29 to 17.51)
p = 0.423
-
Hepatitis −2.91 (95% CI −13.88 to 8.06)
p = 0.605
- −2.21 (95% CI 12.87 to 8.45)
p = 0.686
-
Ferritin (>1300) 10.77 (95% CI −1.66 to 23.20)
p = 0.095
- 3.05 (95% CI −9.28 to 15.38)
p = 0.629
Iron Chelation 6.24 (95% CI −6.40 to 18.87)
p = 0.337
- 10.95 (95% CI −1.08 to 22.98)
p = 0.080
-
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HRQoL in thalassemia patients. Details are given in Table 1.
Overall, PedsQL domain scores were collected from 600
patients and 76 parents. Ismail et al. [13] reported the data
obtained on a cohort of 78 Malaysian patients (mean age
11.9 years) and compared the scores to those of 235 healthy
controls. The results showed a 10% to 24% reduction in the
physical, social and school functioning domains of the
patients, regardless of age, gender, ethnicity and household
income. The authors recommended that the Ministry of
Health continue to support these patients with the supply
of free desferal. Cheuk et al. [14] conducted a comparative
study in Hong Kong to evaluate the differences in HRQoL
between 25 transfusion dependent thalassemia patients and
15 patients who underwent hematopoietic stem cell trans-
plantation. PEDsQL scores of the first group were not
significantly different from those of the transplanted
patients, indicating that conventionally treated patients
adapt relatively well to the burden of chronic illness and
treatment. Clarke et al. [15] focused on mothers’ reports of
22 thalassemia children (aged on average 10 years) waiting
for hematopoietic stem cell transplantation. The resultsTable 4 Differences in child and parent PedsQL domain score
PEDsQL scale Patients
Physical Functioning 75 (56.3, 91.40)
Emotional Functioning 85 (60, 100)
Social Functioning 82.50 (60, 91.25)
School Functioning 75.00 (50, 85)
Psychosocial Health Summary 79.15 (61.88, 88.30) 7
Total Summary Score 77.75 (61.45, 88.28) 7showed a significant compromise in HRQoL in spite of the
fact that the children displayed behaviour comparable to
that of the general population.
Thavorncharoensap et al. [16] evaluated PEDsQL scores
in 315 thalassemia children and adolescents in Thailand.
Again, the school functioning subscale scored the lowest,
with a mean of 67.9 (69.4 in our report). Age at onset of
anemia, age at first transfusion, irregular iron chelation
therapy and low pre-transfusion hemoglobin levels were
factors significantly affecting HRQoL. The authors sug-
gested the introduction of suitable programs aimed at pro-
viding psychosocial support and a link between the patient,
school officials, the family and the physician. Surapolchai
et al. [17] conducted a study on 75 thalassemia children in
Thailand and were the first to assess HRQoL from both the
patients’ and parents’ perspective. Child self-reports were
negatively influenced by low family income and an onset
age of anemia below 2 years, whereas the negative predictor
of total HRQoL score in parent proxy-reports was the fre-
quency of red blood transfusions.
Finally, Garaibeh et al. [18] compared the outcomes
of PEDsQL obtained on a sample of 128 Jordanians, expressed as median and inter-quartile ranges
Parents Difference (95% CI) P value
75 (55.5, 85.18) 3.75 (−1.55, 7.8) 0.112
75 (50, 95) 10 (2.5, 15) 0.002*
75.8 (65, 90) 0.74 (−3.5, 7.5) 0.576
70 (50, 80) 2.5 (−5, 7.5) 0.465
0.3 (59.58, 83.72) 4.2 (0.85, 7.5) 0.015*
4.35 (60.35, 82.77) 2.45 (4.62, 4.9) 0.047*
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healthy children. The patients had significantly lower
HRQoL mean scores in all dimensions compared to
their healthy counterparts. The lowest mean score was
reported for the school domain (46.7): healthcare provi-
ders, counsellors and school teachers have an important
role in helping children to overcome this problem.
Many aspects of these previous reports underline the ef-
fectiveness of the approach applied in the present study
which offers a unique perspective of HRQoL by evaluating
both child-self and parent-proxy reports.
Conclusions
Although larger studies are warranted, our results show
that a delayed start of iron chelation has a negative im-
pact on total PedsQL scores of both child and parent
reports. Parent ratings of their child’s HRQoL were
lower for emotional functioning, psychosocial function-
ing and total HRQoL, suggesting the need to enhance
the understanding and support of the parents. By
increasing the awareness and knowledge levels of the
parents, we can help sick children in developing coun-
tries to get the best care locally and to thus improve
HRQol. A limitation of the present study was that
although the PedsQL questionnaire is sensitive to cogni-
tive development, we did not perform a complete cogni-
tive or psychological evaluation based on normative
scale scores, which would have been helpful in order to
avoid confounding factors (i.e. cognitive, psychological
or psychiatric problems in parents or children). Another
limitation of the study was that HRQoL meaurements
were obtained in a cross-sectional manner. Further re-
search with a longitudinal study design and the recruit-
ment of a healthy control group is warranted.
Thalassaemia patients and their parents require lifelong
psychological support for prevention of mental health
issues. Several effective psychological strategies are avail-
able. Cognitive-Behavioural Family Therapy (CBFT) can
be an effective psychological approach to children with
beta-thalassaemia major, capable of increasing compliance
to treatment, lessening the emotional burden of disease
and improving the quality of life of caregivers [23]. Over-
all, child self and parent proxy-reports represent a valid
methodological approach which should be highly recom-
mended for investigation of HRQoL in pediatric patients.
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